U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07640425) titled 'Safety and Efficacy Study of Collagenase CNT201 Injection for Treatment of Dupuytren's Contracture' on Aug. 23, 2024.

Brief Summary: This trial is a multicenter, Phase 1/2, study to assess the safety, tolerability, efficacy, PK, and immunogenicity of CNT201 in adult participants with DC (Dupuytren's Contracture).

Study Start Date: July 23, 2024

Study Type: INTERVENTIONAL

Condition: Dupuytren Contracture Dupuytren Disease of Finger

Intervention: DRUG: [Step1] CNT201 First-dose

CNT201: recombinant collagenase

* Unit Dose Strength(s)/ Dosage Level(s): 0.1 mg/cord

DRUG: [Step1] CNT201 Low-dose

CNT201: recombinant collagenase ...